Insomnia disorder

New England Journal of Medicine

Volumn 373, Issue 15, 2015, Pages 1437-1444

  Winkelman, John W ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; BENZODIAZEPINE RECEPTOR STIMULATING AGENT; DOXEPIN; ESZOPICLONE; GABAPENTIN; HYDROCORTISONE; HYPNOTIC AGENT; LORAZEPAM; MIRTAZAPINE; PLACEBO; RAMELTEON; SUVOREXANT; TEMAZEPAM; TRAZODONE; TRIAZOLAM; ZOLPIDEM; ANTIDEPRESSANT AGENT; HYPNOTIC SEDATIVE AGENT;

AGED; ANTEROGRADE AMNESIA; ANTICHOLINERGIC SYNDROME; ARTHRITIS; ARTICLE; BEDTIME DOSAGE; CASE REPORT; COGNITIVE THERAPY; DAYTIME SOMNOLENCE; DEPRESSION; DISEASE SEVERITY; DIZZINESS; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FATIGUE; FEMALE; GLUCOSE INTAKE; HUMAN; HYPERTENSION; INSOMNIA; LOW DRUG DOSE; METABOLIC RATE; MOOD DISORDER; OBESITY; PATHOPHYSIOLOGY; PATIENT WORRY; POLYSOMNOGRAPHY; PREVALENCE; PRIMARY INSOMNIA; PRIORITY JOURNAL; RELAXATION TRAINING; REM SLEEP; RESTLESS LEGS SYNDROME; SELECTIVE ATTENTION; SIDE EFFECT; SLEEP AROUSAL DISORDER; SLEEP DISORDER; SLEEP DISORDERED BREATHING; SLEEP WAKING CYCLE; SLEEP WALKING; TASTE DISORDER; THOUGHT DISORDER; WEIGHT GAIN; COMPLICATION; MALE; PRACTICE GUIDELINE; SLEEP INITIATION AND MAINTENANCE DISORDERS;

AGED; ANTIDEPRESSIVE AGENTS; COGNITIVE THERAPY; FEMALE; HUMANS; HYPNOTICS AND SEDATIVES; MALE; OVERWEIGHT; PRACTICE GUIDELINES AS TOPIC; SLEEP INITIATION AND MAINTENANCE DISORDERS; TRAZODONE;

EID: 84943528220     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMcp1412740     Document Type: Article

References (51)

1. Ohayon MM. Epidemiology of insomnia: what we know and what we still need to learn. Sleep Med Rev 2002; 6: 97-111.
2. Roth T, Coulouvrat C, Hajak G, et al. Prevalence and perceived health associated with insomnia based on DSM-IV-TR; International Statistical Classification of Diseases and Related Health Problems, tenth revision; and Research Diagnostic Criteria/ International Classification of Sleep Disorders, second edition criteria: results from the America Insomnia Survey. Biol Psychiatry 2011; 69: 592-600.
3. Kyle SD, Morgan K, Espie CA. Insomnia and health-related quality of life. Sleep Med Rev 2010; 14: 69-82.
4. Shahly V, Berglund PA, Coulouvrat C, et al. The associations of insomnia with costly workplace accidents and errors: results from the America Insomnia Survey. Arch Gen Psychiatry 2012; 69: 1054-63.
5. Laugsand LE, Strand LB, Vatten LJ, Janszky I, Bjørngaard JH. Insomnia symptoms and risk for unintentional fatal injuries-The HUNT Study. Sleep 2014; 37: 1777-86.
6. Ribeiro JD, Pease JL, Gutierrez PM, et al. Sleep problems outperform depression and hopelessness as cross-sectional and longitudinal predictors of suicidal ideation and behavior in young adults in the military. J Affect Disord 2012; 136: 743-50.
7. Shekleton JA, Flynn-Evans EE, Miller B, et al. Neurobehavioral performance impairment in insomnia: relationships with self-reported sleep and daytime functioning. Sleep 2014; 37: 107-16.
8. Edinger JD, Wyatt JK, Stepanski EJ, et al. Testing the reliability and validity of DSM-IV-TR and ICSD-2 insomnia diagnoses: results of a multitrait-multimethod analysis. Arch Gen Psychiatry 2011; 68: 992-1002.
9. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington, VA: American Psychiatric Publishing, 2013.
10. Ford DE, Kamerow DB. Epidemiologic study of sleep disturbances and psychiatric disorders: an opportunity for prevention? JAMA 1989; 262: 1479-84.
11. Walsh JK, Coulouvrat C, Hajak G, et al. Nighttime insomnia symptoms and perceived health in the America Insomnia Survey (AIS). Sleep 2011; 34: 997-1011.
12. Ohayon MM, Roth T. Place of chronic insomnia in the course of depressive and anxiety disorders. J Psychiatr Res 2003; 37: 9-15.
13. Baglioni C, Battagliese G, Feige B, et al. Insomnia as a predictor of depression: A meta-analytic evaluation of longitudinal epidemiological studies. J Affect Disord 2011; 135: 10-9.
14. Laugsand LE, Vatten LJ, Platou C, Janszky I. Insomnia and the risk of acute myocardial infarction: A population study. Circulation 2011; 124: 2073-81.
15. Laugsand LE, Strand LB, Platou C, Vatten LJ, Janszky I. Insomnia and the risk of incident heart failure: A population study. Eur Heart J 2014; 35: 1382-93.
16. Fernandez-Mendoza J, Vgontzas AN, Liao D, et al. Insomnia with objective short sleep duration and incident hypertension: The Penn State Cohort. Hypertension 2012; 60: 929-35.
17. Vgontzas AN, Liao D, Pejovic S, Calhoun S, Karataraki M, Bixler EO. Insomnia with objective short sleep duration is associated with type 2 diabetes: A population-based study. Diabetes Care 2009; 32: 1980-5.
18. Li Y, Zhang X, Winkelman JW, et al. Association between insomnia symptoms and mortality: A prospective study of U.S. men. Circulation 2014; 129: 737-46.
19. Vgontzas AN, Fernandez-Mendoza J, Liao D, Bixler EO. Insomnia with objective short sleep duration: The most biologically severe phenotype of the disorder. Sleep Med Rev 2013; 17: 241-54.
20. Morin CM, Bélanger L, LeBlanc M, et al. The natural history of insomnia: A population-based 3-year longitudinal study. Arch Intern Med 2009; 169: 447-53.
21. Bonnet MH, Arand DL. Hyperarousal and insomnia: state of the science. Sleep Med Rev 2010; 14: 9-15.
22. Harvey AG, Tang NK. (Mis)perception of sleep in insomnia: A puzzle and a resolution. Psychol Bull 2012; 138: 77-101.
23. Edinger JD, Ulmer CS, Means MK. Sensitivity and specificity of polysomnographic criteria for defining insomnia. J Clin Sleep Med 2013; 9: 481-91.
24. Nierenberg AA, Keefe BR, Leslie VC, et al. Residual symptoms in depressed patients who respond acutely to fluoxetine. J Clin Psychiatry 1999; 60: 221-5.
25. Schutte-Rodin S, Broch L, Buysse D, Dorsey C, Sateia M. Clinical guideline for the evaluation and management of chronic insomnia in adults. J Clin Sleep Med 2008; 4: 487-504.
26. Edinger JD, Olsen MK, Stechuchak KM, et al. Cognitive behavioral therapy for patients with primary insomnia or insomnia associated predominantly with mixed psychiatric disorders: A randomized clinical trial. Sleep 2009; 32: 499-510.
27. Trauer JM, Qian MY, Doyle JS, W Rajaratnam SM, Cunnington D. Cognitive behavioral therapy for chronic insomnia: A systematic review and meta-analysis. Ann Intern Med 2015 June 9 (Epub ahead of print).
28. Mitchell MD, Gehrman P, Perlis M, Umscheid CA. Comparative effectiveness of cognitive behavioral therapy for insomnia: A systematic review. BMC Fam Pract 2012; 13: 40.
29. Morin CM, Vallières A, Guay B, et al. Cognitive behavioral therapy, singly and combined with medication, for persistent insomnia: A randomized controlled trial. JAMA 2009; 301: 2005-15.
30. Buysse DJ, Germain A, Moul DE, et al. Efficacy of brief behavioral treatment for chronic insomnia in older adults. Arch Intern Med 2011; 171: 887-95.
31. Ritterband LM, Thorndike FP, Gonder-Frederick LA, et al. Efficacy of an Internet-based behavioral intervention for adults with insomnia. Arch Gen Psychiatry 2009; 66: 692-8.
32. Morgenthaler T, Kramer M, Alessi C, et al. Practice parameters for the psychological and behavioral treatment of insomnia: an update: an American Academy of Sleep Medicine report. Sleep 2006; 29: 1415-9.
33. Matthews EE, Arnedt JT, McCarthy MS, Cuddihy LJ, Aloia MS. Adherence to cognitive behavioral therapy for insomnia: A systematic review. Sleep Med Rev 2013; 17: 453-64.
34. Kyle SD, Miller CB, Rogers Z, Siriwardena AN, Macmahon KM, Espie CA. Sleep restriction therapy for insomnia is associated with reduced objective total sleep time, increased daytime somnolence, and objectively impaired vigilance: implications for the clinical management of insomnia disorder. Sleep 2014; 37: 229-37.
35. Bertisch SM, Herzig SJ, Winkelman JW, Buettner C. National use of prescription medications for insomnia: NHANES 1999-2010. Sleep 2014; 37: 343-9.
36. Morin CM, Koetter U, Bastien C, Ware JC, Wooten V. Valerian-hops combination and diphenhydramine for treating insomnia: A randomized placebo-controlled clinical trial. Sleep 2005; 28: 1465-71.
37. Glass JR, Sproule BA, Herrmann N, Busto UE. Effects of 2-week treatment with temazepam and diphenhydramine in elderly insomniacs: A randomized, placebo-controlled trial. J Clin Psychopharmacol 2008; 28: 182-8.
38. Winkler A, Auer C, Doering BK, Rief W. Drug treatment of primary insomnia: A meta-analysis of polysomnographic randomized controlled trials. CNS Drugs 2014; 28: 799-816.
39. Walsh JK, Krystal AD, Amato DA, et al. Nightly treatment of primary insomnia with eszopiclone for six months: effect on sleep, quality of life, and work limitations. Sleep 2007; 30: 959-68.
40. Krystal AD, Erman M, Zammit GK, Soubrane C, Roth T. Long-term efficacy and safety of zolpidem extended-release 12.5 mg, administered 3 to 7 nights per week for 24 weeks, in patients with chronic primary insomnia: A 6-month, randomized, double-blind, placebo-controlled, parallel-group, multicenter study. Sleep 2008; 31: 79-90.
41. Smink BE, Egberts AC, Lusthof KJ, Uges DR, de Gier JJ. The relationship between benzodiazepine use and traffic accidents: A systematic literature review. CNS Drugs 2010; 24: 639-53.
42. Woolcott JC, Richardson KJ, Wiens MO, et al. Meta-analysis of the impact of 9 medication classes on falls in elderly persons. Arch Intern Med 2009; 169: 1952-60.
43. Billioti de Gage S, Moride Y, Ducruet T, et al. Benzodiazepine use and risk of Alzheimer's disease: case-control study. BMJ 2014; 349: g5205.
44. Roehrs T, Bonahoom A, Pedrosi B, Rosenthal L, Roth T. Treatment regimen and hypnotic self-administration. Psychopharmacology (Berl) 2001; 155: 11-7.
45. Morin CM, Bélanger L, Bastien C, Vallières A. Long-term outcome after discontinuation of benzodiazepines for insomnia: A survival analysis of relapse. Behav Res Ther 2005; 43: 1-14.
46. Krystal AD, Lankford A, Durrence HH, et al. Efficacy and safety of doxepin 3 and 6 mg in a 35-day sleep laboratory trial in adults with chronic primary insomnia. Sleep 2011; 34: 1433-42.
47. Herring WJ, Connor KM, Ivgy-May N, et al. Suvorexant in patients with insomnia: results from two 3-month randomized controlled clinical trials. Biol Psychiatry 2014 October 23 (Epub ahead of print).
48. Michelson D, Snyder E, Paradis E, et al. Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: A phase 3 randomised, double-blind, placebo-controlled trial. Lancet Neurol 2014; 13: 461-71.
49. Mayer G, Wang-Weigand S, Roth-Schechter B, Lehmann R, Staner C, Partinen M. Efficacy and safety of 6-month nightly ramelteon administration in adults with chronic primary insomnia. Sleep 2009; 32: 351-60.
50. Ferracioli-Oda E, Qawasmi A, Bloch MH. Meta-analysis: melatonin for the treatment of primary sleep disorders. PLoS One 2013; 8(5): e63773.
51. National Institutes of Health. Stateof-The-Science Conference Statement on Manifestations and Management of Chronic Insomnia in Adults, June 13-15, 2005. Sleep 2005; 28: 1049-57.